Secukinumab Shows Higher Symptomatic Improvement and Lower Cost Per Response vs. Adalimumab After One Year Treatment of Active Ankylosing Spondylitis- A Cost Per Responder Analysis from A Chilean Perspective
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.2973
https://www.valueinhealthjournal.com/article/S1098-3015(17)33307-7/fulltext
Title :
Secukinumab Shows Higher Symptomatic Improvement and Lower Cost Per Response vs. Adalimumab After One Year Treatment of Active Ankylosing Spondylitis- A Cost Per Responder Analysis from A Chilean Perspective
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)33307-7&doi=10.1016/j.jval.2017.08.2973
First page :
A937
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
2719